We are excited to announce that we have secured a funding round of € 8M ($ 9.1M). This financial support will allow us to continue developing our platform technology and to establish a global commercial organization to address unmet needs in the label-free cell counting market improving the day-to-day operations of our clients. The funds will also be used to further validate our technology in the in vitro diagnostics industry where it has the potential for early disease detection at a reduced cost.